rusfertide
rusfertide: developed by 1 company · 2 clinical trials tracked.
rusfertide evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could rusfertide → PTGX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Protagonist Therapeutics, Inc (PTGX) Polycythemia vera (erythrocytosis in patients with PV) | Phase 3 |
Clinical Trials (2)
A Phase 2 Open-Label Trial to Evaluate the Efficacy and Safety of the Hepcidin Mimetic Rusfertide (TAK-121) in Chinese Patients With Polycythemia Vera
Primary endpoint: Percentage of Participants Achieving a Response Starting at Week 20 Through Week 32
A Phase 2 Open-label Trial to Evaluate the Efficacy and Safety of Rusfertide in Japanese Patients With Polycythemia Vera
Primary endpoint: Percentage of Participants Achieving a Response Starting at Week 20 through Week 32
Frequently asked questions
Who is developing rusfertide?
rusfertide is being developed by Protagonist Therapeutics, Inc.
How many clinical trials involve rusfertide?
BioSniper tracks 2 clinical trials involving rusfertide.